Pharmacokinetics/pharmacodynamics of chloroquine and artemisinin-based combination therapy with primaquine.

ABSTRACT:

Background

Activation of hypnozoites of vivax malaria causes multiple clinical relapses, which contribute to the Plasmodium vivax burden and continuing transmission. Artemisinin-based combination therapy (ACT) is effective against blood-stage P. vivax but requires co-administration with primaquine to achieve radical cure. The therapeutic efficacy of primaquine depends on the generation of a therapeutically active metabolite via cytochrome P450 2D6 (CYP2D6). Impaired CYP2D6 metabolism has been associated with primaquine treatment failure. This study investigated the association between impaired CYP2D6 genotypes, drug-exposure to the long-acting ACT component (schizonticidal drugs) and tolerance and efficacy.

Methods

Adult patients with acute vivax malaria were enrolled in a r

SUBMITTER: Daher A 

PROVIDER: S-EPMC6757423 | biostudies-literature | 2019 Sep

REPOSITORIES: biostudies-literature